
Lionheart Stimulus 240 Stimulator
The Lionheart Stimulus™ 240 Stimulator is a professional-grade 4-channel electrotherapy…
$21,995.00

SkinStim is a Leonhardt Ventures asset incubating in the Leonhardt’s Launchpads incubator. The company focuses on using patented bioelectric signaling to “turn back on” Tropoelastin expression for non-invasive skin regeneration, elasticity restoration, and DNA repair.
Discover our background, mission, and the world-class research driving our next-generation medical technology.
SkinStim™ is a clinical-stage regenerative medicine company dedicated to reversing the biological effects of skin aging. Our mission is to move beyond temporary topical fixes by utilizing patented bioelectric signaling sequences that unlock the body’s innate ability to regenerate youthful, healthy, and elastic skin tissue.
The hallmark of skin aging is the loss of Tropoelastin, the protein responsible for skin elasticity. Humans naturally stop producing tropoelastin around age 9. SkinStim™ has pioneered a breakthrough: a patented bioelectric signal designed to “turn back on” the tropoelastin expression switch. By combining this signaling with stem cell homing factors (SDF-1) and DNA repair proteins (IGF-1), we offer a comprehensive solution to regenerate skin from the inside out.
The global skincare market is valued at $177 billion annually, with over one billion people seeking youthful skin solutions. SkinStim™ addresses the $1.6 billion skin burn and wound recovery market alongside the massive aesthetic sector. The company is currently entering clinical studies in Los Angeles, Utah, South Africa, and Pittsburgh.
SkinStim™ is built upon over 40 years of medical innovation led by Howard Leonhardt and the Leonhardt Ventures team:
Want to learn more? Browse our clinical resources and scientific publications on our latest updates and insights.

Executive Chairman & CEO
30 years of experience. Inventor with more than 21 issued U.S. patents and dozens more pending. Developed, commercialized, and successfully...

Executive Chairman & CEO
30 years of experience. Inventor with more than 21 issued U.S. patents and dozens more pending. Developed, commercialized, and successfully led multiple healthcare products to market leadership and exit.

Chief Medical Officer
Author of 241 peer-reviewed publications, with experience helping manage over 80 clinical trials, and over a decade of leadership as...

Chief Medical Officer
Author of 241 peer-reviewed publications, with experience helping manage over 80 clinical trials, and over a decade of leadership as Chairman of Cardiovascular Medicine at a major university. Co-editor of a leading textbook on stem cell regeneration.

Vice President Business Development
Over 25 yers experience developing life science products.

Vice President Business Development
Over 25 yers experience developing life science products.

Chief Advisor Regenerative Therapies
Over 30 years experience organ regeneration research.

Chief Advisor Regenerative Therapies
Over 30 years experience organ regeneration research.

Vice President Bioelectric Regeneration Research
Over 25 years experience bioelectric and biologics organ regeneration research experience.

Vice President Bioelectric Regeneration Research
Over 25 years experience bioelectric and biologics organ regeneration research experience.

Chief Advisor Biologics
20 years biologics research experience.

Chief Advisor Biologics
20 years biologics research experience.
Discover the science and innovation driving our advanced solutions, designed to deliver safe, effective, and transformative results.
What if a simple bioelectric stimulation sequence could reverse the damaging effects of skin aging? What if combining bioelectric stimulation with repeat applications of a stem cell media-based composition in a nutrient-rich hydrogel could therapeutically reverse the effects of aging skin?
This is our vision. This is our mission. This is our goal. Introducing SkinStim™: Unlocking your body’s natural healing capabilities to regenerate your skin back to a youthful and healthy appearance.
SkinStim™ serves as a non-invasive augmentation of the body’s natural electrophysiology through frequency, polarity balancing, and homeostasis. Microcurrent stimulation (electroporation) mirrors the body’s natural current flow to encourage cell physiology and growth.
Patented and patent-pending signals control the precision release of:
Our platform utilizes high-precision stimulators manufactured by Mettler Electronics with FDA 510K Market Clearance for muscle re-education, relaxation of muscle spasms, and increased local circulation.
Clinical & Consumer Systems:
For severe and advanced cases, we combine 19 regenerative bioelectric signals with our proprietary biologic solutions:
SkinStim™ bioelectric microcurrent is designed to:
The SkinStim Consumer Product is clinic-quality bioelectric stimulation in a handheld device.
Don’t see your question? Reach out and our clinical team will respond personally.
SkinStim SS-15 mixed stem cell based composition is available under Investigational Device Exemption at this time in selected countries for regulatory clearance has been received. Not available for sale.
The SkinStim combination candidate skin regeneration therapy in part or full is not yet proven to be safe and effective in properly controlled clinical trials.
510K market clearance for the SkinStim Mettler bioelectric stimulator is limited to improved blood circulation, mild pain relief and accelerated muscle tone healing only. No other indications of use or performance claims are authorized. The product is not proven yet for skin regeneration.
Only patented bioelectric signal to control stem cell homing via SDF-1(stromal derived factor 1) release. Over a dozen studies have documented that SDF-1 is the key stem cell homing factor protein in nature. We had our first bioelectric stem cell homing patent issued in 2005 and published our first SDF-1 paper in 2012.
Only known patent pending bioelectric signal for turning switch back on for tropoelastin release. Tropelastin creates elasticity of tissues including skin. We lose tropoelastin production when we are about 9 years old. We figured out how to turn that switch back on.
Only known patent pending bioelectric signal for controlling IGF-1 (insulin growth factor) release for DNA repair. This protein is known to repair skin cells damaged from aging, sun and smoke damage.
Only known patent pending bioelectric signaling sequence for growing functionally new mature (true endothelium lining) blood vessels for improving circulation. Sequence includes VEGF, SDF-1, EGF, PDGF HGDF, eNOS, CXCL5, PDGF, tropoelastin, follistatin.
Only known patent pending bioelectric signal sequence for repairing damaged muscle tissue via controlled release of follistatin. Our bioelectric stimulator has FDA 510K market clearance for improving blood circulation, improving muscle tone and accelerated healing of injuries.
How does bioelectric signaling work? It communicates directly with the DNA and the membrane of cells to give them very specific instructions on what proteins to produce, what cell membrane pores to open and close and what ionic communication channels to activate or deactivate. The bioelectric signaling is just like the computer program that gives instructions to the micro processors, semi-conductors and diodes of a computer. We use natural signals that are the same ones used in nature to recruit stem cells, repair damaged skin, improve circulation and heal organs. We just amplify these natural signals and extend their duration under control. These natural bioelectric signals are at work every day to repair your body of small injuries such a knee or elbow scrape and work very well. When there is severe damage they are overwhelmed and the body needs some additional help. Some functions such as tropelasin release turn off in humans at an early age as part of our programmed pathway towards aging and death. We have learned to turn some of these switches back on.
Only skin regeneration therapy that in severe cases combines bioelectrics with biologics for best results. Our basic biologics package includes amniotic fluid, only available at room temperature storage and time release PRF (platelet rich fibrin). PRF time release skin repairing growth factors for over 21 days. Both amniotic fluid and PRF have been part of over a dozen pre-clinical and clinical studies for skin regeneration and other healing applications. We just filed a new patent on the combination of bioelectric signaling and PRF. Amniotic fluid has become widely used in the USA for diabetic foot and leg ulcer healing with between 140 and 240 growth factors within the solution and membranes.
Our patent pending SS-15 skin regeneration composition is for very advanced skin damage repair including burn recovery. It is comprised of fifteen components which include adipose derived stem cells, growth factors, amniotic fluid, PRF, selected exosomes, selected alkaloids, selected micro RNAs, nutrient engineered hydrogel, skin matrix and oxygenated nano-particles. All of these components have been studied separately with numerous supporting peer review published papers. We are planing now clinical trials for the full fifteen component mixed composition “skin regeneration cocktail” combined with bioelectric stimulation.
No team has more experience than our team in bioelectric and biologics based organ regeneration. We published our first stem cell regeneration paper in 1989 in The Physiologist with Dr. Race Kao and Dr. George Magovern and in 1999 our first bioelectric regeneration paper in CIRCULATION the Journal of the American Heart Association working with Dr. Shinich Kanno via VEGF expression.
Our Chief Medical Officer Dr. Leslie Miller has been a part of over 80 FDA authorized clinical trials and is author or co-author of over 240 publications including one of the leading textbooks on stem cell based regeneration.
SkinStim is supported by over 140 experienced advisors and mentors as part of the Leonhardt’s Launchpads innovation and startup accelerator which includes a number of the leading stem cell scientists in the world.
The SkinStim full treatment protocol includes in clinic bioelectric, infrared light, PRF, amniotic fluid, micro needling, electro acupuncture and electro massaging in combination and in very severe cases also the SS-15 skin regeneration composition with includes adipose derived stem cells. At home the patient continues mobile bioelectric and light treatments, nutrient hydrogel and stem cell extract Lumenaire skin cream/gel treatments and repeated electro massages. Clinicians and patients can choose any combination of the above.
We are signing up Skin Clinics right now to participate in the evaluation of our SkinStim Basic skin regeneration package = bioelectric + light + amniotic fluid + PRF + micro needling + electro acupuncture + electro massaging followed by at home use of Lumenaire cream/gel.
We are completing pre-clinical studies to apply to the FDA or OUS regulatory authorities to begin studies of our Skin Advanced skin regeneration package which includes the fifteen component SS-15 composition = adipose derived stem cells, + growth factors + amniotic fluid + PRF + selected exosomes + selected alkaloids + selected micro RNAs, nutrient engineered hydrogel, skin matrix and oxygenated nano-particles.
Our team has discovered 19 bioelectric signals so far for controlling specific protein expressions relating to healing organs including skin and we are working every day to discover more.
Our management team and board has brought a number of products from concept to market leadership and successful exit for investors over the years including the Poly-Cath cardiovascular balloon catheters in the 1980’s exited to Nippon Zeon, stent grafts and percutaneous heart valves exited to Medtronic AVE in the 1990s.
It is first and foremost controlled release of regenerative proteins via precise bioelectric signals. We have patented or patent pending of 19 bioelectric signals at this time and are adding more as our research continues. The primary signal is the one that releases SDF-1 which is a known stem cell homing factor. This protein recruits stem cells from your own fat, bone marrow and circulating blood to the stimulated regions of your face and neck. The second most important bioelectric signal sequence is the one for producing release of tropoelastin which is known to increase elasticity of tissues. We also have bioelectric signals for IGF-1 (DNA repair) and EGF, HGF, PDGF, eNOS and HIF1a all which are known to improve blood circulation and follistatin which is known to improve muscle tone.
We combine the bioelectric stimulation with our proprietary skin cream produced by our partnership company Luminaire and in severe skin regeneration cases such as burns, where permitted by regulatory authorities or in clinical trials, we also utilize our patent pending SS-15 fifteen component skin regeneration composition comprised of stem cells, growth factors, amniotic fluid, platelet rich fibrin, exosomes, selected Micro RNAs, engineered nutrient hydrogel, selected alkaloids such as harming and skin matrix.
We initiated a collaboration with Dr. Robert O. Becker the Author of The Body Electric in 1985. We completed our first stem cell based organ regeneration large animals studies in 1988 working with Dr. Race Kao and Dr. George Magovern which were published in The Physiologist in 1989. Dr. Doris Taylor one of our Scientific Advisory Board members published in Nature Medicine a paper on muscle stem cell regeneration of heart in 1999. In 1999 we published our first paper on bioelectric regeneration in CIRCULATION the Journal of the American Heart Association working with Dr. Shinichi Kanno. From 1999 to present we have raised and invested more than $145 million into organ regeneration research. In May 2001 we led a team in The Netherlands with visiting U.S. collaborators that completed the historic first-ever non-surgical stem cell based repair of a human heart. We went on to lead and sponsor Pilot, Phase I, Phase II and Phase II/III studies working with 33 centers in the USA and a half dozen in Europe. These studies were published in The Journal of the American College of Cardiology, American Heart Journal, EuroIntervention and European Heart Journal. The team filed their first stem cell delivery system patent application in 1995 for ProCell based on work that began in 1988 – https://www.google.com/patents/US5693029. Howard Leonhardt the company founder has 21 issued U.S. patent and about 100 new patent claims pending with the USPTO all related to organ regeneration and recovery. In 2000 the team began filing its first patents for bioelectric regeneration including in combinations with stem cells, growth factors, nutrient hydrogels and matrixes. In 2008 the team launched work that led to collaborations and resulting studies of applying both bioelectric stimulation, stem cells, amniotic fluid and growth factors to healing skin wounds. One of these collaborative studies resulted in a publications in the International Wound Journal utilizing non-invasive wireless bioelectric stimulation methods – http://calstockexchange.com/wp-content/uploads/2014/09/WMCS_International_Wound_Journal_Jan_2014.pdf. Separate related studies were completed with 16 patients in Czech Republic (stem cells alone) and 8 patients in Mexico (bioelectric stimulation alone). The SkinStim by MyoStim Skin team believes no other group has a much experience in bioelectric, stem cell, growth factor, nutrient hydrogel and matrix based organ regeneration. Via Leonhardt Ventures and Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. we have over 140 experienced team members and advisors – which includes over 35 scientific and clinical leaders in organ regeneration research – https://calxstars.com/scientific-advisory-board/
Short answer – Precise bioelectric signals give clear instructions to the stimulated cell DNA/RNA to produce specific regenerative proteins on demand. Bioelectric signals give clear instructions to cell membranes on what to let in and what to let out and serve as an equivalent or surrogate of environmental stimuli to cause a cell action in response.
Bioelectric Signals in Regeneration
Alongside the biochemical signals that underlie regenerative ability functions an important and powerful system of biophysical controls that orchestrates cell behavior into the patterning needs of the host organism. Bioelectricity refers to the slow changes in ion content and resting membrane voltage (Vmem) that are present in all cells. Distinct from the rapid action potentials of excitable nerve and muscle, and from the effects of external electromagnetic field exposure, it is now known that endogenous gradients of voltage serve as instructive signals regulating cell proliferation, differentiation, and migration (reviewed in (Nuccitelli, 2003; McCaig et al., 2005; Blackiston et al., 2009; McCaig et al., 2009; Sundelacruz et al., 2009)). Even more exciting than the control of position, type, and number at the level of individual cells, is the role of bioelectric signals in large-scale pattern formation during cancer suppression, embryogenesis, and regeneration (Lund, 1947; Nuccitelli et al., 1986; Levin, 2007, 2009). Standing gradients of voltage and ion fluxes among cells serve to regionalize tissues as pre-patterns for gene expression domains (Burr and Hovland, 1937; Burr and Sinnott, 1944; Vandenberg et al., 2011), provide coordinates to guide morphogenetic rearrangements (Shi and Borgens, 1995), dictate anatomical identity and polarity of actively patterning tissues (Marsh and Beams, 1949; Kurtz and Schrank, 1955; Marsh and Beams, 1957; Levin et al., 2002; Adams et al., 2006; Beane et al., 2011), and serve as master-regulators for initiating the development of specific organs and the regeneration of whole appendages (Borgens et al., 1979; Jenkins et al., 1996; Pai et al., 2012). (see full reference link below).
TRANSDUCING BIOELECTRIC SIGNALS INTO EPIGENETIC PATHWAYS DURING TADPOLE TAIL REGENERATION
Short answer – Traditional microcurrent devices were designed to accelerate healing via “current of injury” signaling, to improve mildly blood circulation and muscle tone and provide mild pain relief. Traditional TENS devices were designed to lower pain. Nearly all of these devices have very fuzzy noisy signals compared to new modern precise bioelectric signaling stimulators, such as those used and programmed by SkinStim. Traditional microcurrent facial devices do not have specific precise signals or sequences for controlling the release of specific regeneration promoting proteins on demand and even if programmed with these signals do not have the clarity of signal for the body to understand the instruction. When they send their signals the body says back “what I cannot understand you, speak more clearly, what do you want me to do?”. Bioelectric stimulators, such as SkinStim’s, have precise programming to deliver precise clear signals to control protein expressions on demand. These controlled protein expressions are for very specific purposes. See below.
Examples of controlled protein expressions only possible with precise bioelecdtric signaling with a high precision stimulator with clarity of signals.
Traditional microcurent or TENS facials do not control with preciseness any of the above. At best they provide a temporary slight improvement of blood circulation if there is a surface wound these general “current of injury” signal have demonstrated accelerated healing.
One of the first studies documenting the positive effects of microcurrent stimulation on this problem was by the team of Wolcott et all in 1969. These researchers applied stimulation in the range of 200-800 uA to a wide variety of wounds using alternating current polarities. A control group was treated with ordinary wound care methods The treated group showed 200-35O% faster healing rates than controls, with stronger tensile strength of scar tissue and antibac- terial effects in infected wounds.
Want to learn more? Browse our clinical resources and scientific publications on our comprehensive suite of targeted treatments.
Official IRB-approved study protocols, FDA 510K clearances, and clinical data for the SkinStim™ regeneration platform.
Scientific journals focusing on how low-level currents (Microcurrent) promote cellular repair and bioelectric signaling.
Research papers on the specific proteins activated by SkinStim™ signals to reverse DNA damage and restore elasticity.
Clinical data on the use of placental and adipose-derived biologics for deep tissue rejuvenation.
Research on the delivery systems (scaffolds) and molecular regulators (MicroRNA) used in the SS-15 regimen.
Resources regarding the use of PRF for aesthetics and mandatory clinical documentation for patients.
Want to learn more? Browse our clinical resources and scientific publications on our latest updates and insights.
Important Warning, Disclaimer & Safety Information
Caution: Investigational Use Only. Early-stage development is available for investigational use only in selected countries at this time—safety and efficacy have not yet been proven via statistically significant and controlled clinical trials. Not available for sale in the USA.
The OEM manufacturer of our bioelectric microcurrent and TENS combination stimulator for SkinStim™ based in Anaheim, California, has FDA 510K clearance (K113017 / K031077) for improving blood circulation, mild pain relief, accelerated healing, and muscle tone improvement. All other indications listed below under the preface “designed to” or “intended to” are currently under study with data being gathered to submit to the FDA a request for expanded labeling indications of use.
SkinStim’s cells, membranes, and matrix scaffolds are regulated by the FDA as an HCT/P – HOMOLOGOUS EXEMPTION RULE – solely under Section 361 of the Public Health Service Act and 21 CFR 1271. Utilization of these technologies is limited to healthcare professionals and facilities capable of handling such tissue products. Proper aseptic procedural and/or surgical handling is mandatory; failure to ensure proper technique may result in infection, serious injury, or death.
If you are seeking a non-invasive alternative to standard cosmetic treatments, you may be a candidate for our IRB-approved clinical registry study. Join over one billion people worldwide in seeking a regenerative, bioelectric solution for total skin restoration.